Maze Therapeutics, Inc. (MAZE) — 10-Q Filings
All 10-Q filings from Maze Therapeutics, Inc.. Browse 3 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (3)
-
MAZE Swings to $96.5M Loss Amid Zero License Revenue, R&D Spikes
— Nov 6, 2025 Risk: high
Maze Therapeutics, Inc. (MAZE) reported a significant net loss of $96.552 million for the nine months ended September 30, 2025, a stark contrast to the net inco -
Maze Therapeutics Swings to Loss Amid IPO, R&D Spend
— Aug 12, 2025 Risk: high
Maze Therapeutics, Inc. (MAZE) reported a significant shift in its financial performance for the quarter ended June 30, 2025, moving from a net income of $139.0 -
Maze Therapeutics Files Q1 2025 10-Q
— May 14, 2025 Risk: medium
Maze Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, including
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX